Next 10-11 FEB 2020 will be the 5th @EUCROF Conference on Clinical Research in Amsterdam
Next 10-11 FEB 2020 will be the 5th @EUCROF Conference on Clinical Research in Amsterdam
Sermes CRO obtains the certificate of excellence in Business Management
On November 19, Sermes CRO obtained the certificate of excellence in Business Management from elEconomista.es and einforma.es.
ISPOR 2019
Sermes CRO, and as a member of PSN Research, is attending the ISPOR 2019 Copenhagen Congress (The worldwide leading professional society in Heath Economics and Outcomes Research). Society’s goal is to promote HEOR excellence in order to improve global healthcare decision-making.
Sermes CRO continues their international expansion process with their first Headquarters in Latin America (LATAM)
SERMES CRO continues their internationalization process with the opening of an office in Santiago de Chile consolidating their service´s coverage in LATAM.
Sermes CRO at the Colloquium-discussion “Sport YES, Injuries NO”, organized by the OAFI Foundation
Sermes CRO as a collaborator of the OAFI Foundation, has been invited on May 29, 2019, to the Colloquium-discussion “Sport YES, Injuries NO”, organized by the OAFI Foundation together with the medical services of Atlético de Madrid.
Sermes CRO awarded as the most Innovative company global supplier 2019 by MSD company (Merck Sharp and Dhome)
Sermes CRO Team, led by their CEO and founder Antonio Berlanga, accompanied by the responsible for clinical research and resposible of business development, has been awarded as the most company as the most Innovative company global supplier 2019 by MSD company (Merck Sharp and Dhome).
“Sermes CRO is committed to investing in the development of specific and technological areas”
From Sermes CRO years ago, we saw how this process came to stay and we bet on it. We invest in teams of specialized people to be able to create our own solutions and manage the information in an autonomous way. Nowadays, we have the necessary tools to give all kinds of services from our CRO/E-cro of high quality, budgetary efficiency and in the shortest time.
Sermes CRO: AEMPS approves the NC1 advance therapy drug for patients with chronic traumatic medullary injury
The NC1 cell therapy drug for patients with chronic traumatic spinal cord injury has been authorized by the AEMPS for public use at hospital use. NC1 has been developed by Dr. Vaquero and Dr. Zurita at Puerta de Hierro University Hospital with the collaboration in the clinical research of Sermes CRO and the Sermes Foundation.
